<DOC>
	<DOCNO>NCT00449878</DOCNO>
	<brief_summary>This clinical trial evaluate efficacy Liprotamase treatment cystic fibrosis ( CF ) patient exocrine pancreatic insufficiency ( PI ) .</brief_summary>
	<brief_title>Liprotamase Efficacy Trial Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency</brief_title>
	<detailed_description>This trial divide four distinct period : 1 . Baseline Period patient take pancreatic enzyme medication . 2 . An Open-Label Treatment Period patient receive ALTU-135 ( liprotamase ) . 3 . Inpatient , Double Blind Treatment Period half patient withdraw treatment receive Placebo . 4 . Second Open-Label Treatment Period patient resume treatment ALTU-135 ( liprotamase ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Females childbearing potential must willing use birth control Diagnosis CF base upon follow criterion : two clinical feature consistent CF ; either genotype two identifiable mutation consistent CF , OR sweat chloride &gt; 60 mEq/L quantitative pilocarpine iontophoresis Clinically stable evidence acute upper low respiratory tract infection PI determine fecal elastase &lt; 100 Âµg/g stool measure screen Able take pancreatic enzyme supplementation form capsule Able perform testing ( e.g. , stool collection ) inpatient stay require study , judge Investigator Baseline coefficient fat absorption ( CFA ) less equal 80 % CFA &gt; 80 % Baseline Pregnancy , breastfeed childbearing potential willing use birth control study History fibrosing colonopathy History liver transplant , lung transplant significant surgical resection bowel Any acute chronic diarrheal illness unrelated PI Unable discontinue enteral tube feeding study Known hypersensitivity food additive Inability consume diet require study , judgment Investigator Participation investigational study drug , biologic , device currently approve marketing within 30 day prior screen Abnormal liver function ( except patient Gilbert Syndrome ) Signs and/or symptom liver cirrhosis , portal hypertension document liver disease unrelated CF Distal intestinal obstruction syndrome ( DIOS ) last six month prior screen Unable discontinue use pancreatic enzyme Any condition Investigator believe would interfere intent study would make participation best interest patient Patient unlikely complete study , determine Investigator</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>cystic fibrosis-related pancreatic insufficiency</keyword>
</DOC>